Plain-language overview
Extracellular vesicles can change after they are collected. Storage temperature, the liquid surrounding them, freezing and thawing, the container, particle aggregation, sterility controls, and the amount of time in storage can all affect the final product.
Keeping an EV preparation cold does not by itself prove that it remains stable. Stability has to be demonstrated for the exact product, formulation, container, and storage conditions.
A meaningful stability program asks whether the product continues to meet its specifications for identity, particle characteristics, purity, potency, and safety-related quality attributes throughout its intended shelf life.
Temperature
Temperature can affect EV membranes, proteins, RNA and other cargo, particle aggregation, and chemical or enzymatic reactions.
Refrigerated storage may be appropriate for short periods for some preparations, while frozen storage is commonly used for longer periods. There is no single storage temperature that can automatically be considered best for every EV product.
A temperature excursion during manufacturing, shipping, thawing, or clinical handling may affect product quality and should be evaluated rather than assumed to be harmless.
Figure 1 placeholder — Temperature
Buffer composition
Buffer composition describes the liquid formulation surrounding the EVs. Its pH, ionic strength, osmolarity, and other ingredients can affect particle behavior and stability.
An excipient may be added to improve stability. A cryoprotectant is an ingredient intended to reduce damage associated with freezing and thawing.
A common research buffer is not automatically the best clinical formulation. The final buffer should be evaluated for product compatibility, intended route of administration, sterility strategy, and stability.
Figure 2 placeholder — Buffer composition
Freeze–thaw cycles
Freeze–thaw cycles repeatedly expose an EV preparation to freezing and warming. Ice formation and changes in local solute concentration can stress membranes and other product components.
The effects can include changes in particle number, size distribution, aggregation, membrane integrity, cargo measurements, or biological activity. Results differ among studies because EV sources, formulations, storage temperatures, freezing rate, thawing rate, and analytical methods differ.
Clinical and laboratory workflows should therefore minimize unnecessary repeated freezing and thawing, and the allowable number of cycles should be supported by product-specific stability data.
Figure 3 placeholder — Freeze–thaw cycles
Container effects
Container effects occur because EV preparations can interact with vials, tubes, syringes, stoppers, filters, and other materials that touch the product.
Particles and proteins can undergo adsorption to container surfaces, especially when concentrations are low. Container material, surface chemistry, headspace, fill volume, agitation, and compatibility with freezing can all matter.
A container-closure system can also contribute an extractable or leachable. Container-closure integrity is important for maintaining the intended environment and protecting product quality.
Figure 4 placeholder — Container effects
Aggregation
Aggregation occurs when EVs or other particles associate into larger structures.
Concentration, freezing and thawing, agitation, pH, ionic conditions, surface interactions, and contaminants can contribute to aggregation. Aggregation can change measured particle number, particle size, filtration behavior, distribution in the body, cellular uptake, and possibly biological activity.
A lower measured particle count does not always mean that particles were destroyed; some may have joined together into aggregates. Stability testing should therefore assess both particle concentration and size or aggregation behavior.
Figure 5 placeholder — Aggregation
Sterility
Sterility is essential for an EV product intended for administration to patients. Storage cannot make a contaminated product sterile.
Sterility has to be built into source control, manufacturing, aseptic processing, the container-closure system, and testing. Relevant controls may include bioburden, endotoxin, mycoplasma, and sterility testing depending on the product and manufacturing process.
A passing sterility test does not replace a well-controlled sterile manufacturing process.
Figure 6 placeholder — Sterility
Shelf life
Shelf life is the period during which a product is expected to remain within its defined specifications when stored under the labeled conditions.
Real-time stability testing follows the product under its intended storage conditions. Accelerated stability or stress studies can help researchers understand how the product may degrade, but they do not automatically prove long-term shelf life.
An expiration date should therefore be supported by stability data for the exact EV product in its final formulation and container.
Figure 7 placeholder — Shelf life
Stability-indicating tests
A stability-indicating assay is a test capable of detecting a meaningful change in the product during storage.
Particle count alone is not enough. Depending on the product, testing may include particle size, aggregation, molecular markers, purity, potency, pH, appearance, and other quality attributes.
Shipping and handling
Shipping can expose an EV product to temperature changes, vibration, agitation, delays, and transfers between containers.
Validated shipping conditions and appropriate temperature monitoring help determine whether the product remained within acceptable conditions before use.
Preparation for administration
Thawing, mixing, dilution, filtration, time spent in a syringe, and the period between preparation and administration can affect product recovery or quality.
Instructions for clinical use should therefore define handling conditions that have been supported by stability and compatibility data.
Questions patients should ask
At what temperature is the EV product stored? What buffer or formulation is used? How many freeze–thaw cycles are allowed? Has the final container been tested for EV loss or compatibility? How is aggregation monitored? How is sterility assured? What real-time stability data support the expiration date? What happens if the product experiences a temperature excursion during shipping?
Bottom line
EV stability is product-specific. Temperature is important, but temperature alone cannot prove that an EV preparation remains suitable for use.
A defensible shelf life is supported by stability-indicating tests performed on the exact product in its final formulation and container, together with appropriate sterility assurance, shipping controls, and clinically relevant handling instructions.
How this review was prepared
This Patient Edition was derived directly from the explicitly approved 0611 Professional Edition and preserves the same seven controlling Points.